Beyond Disease Management: The Promise of Lasting Change in Liver Disease
Every clinical protocol begins with a series of decisions—inclusion criteria, primary endpoints, biomarker assessments, and statistical calculations. But behind every data point is a person hoping for something more: relief from debilitating symptoms, freedom from lifelong treatment, or the possibility of a future without disease.
For millions living with chronic liver conditions, the burden extends far beyond clinical measurements. There is the anxiety of viral rebound, the relentless fatigue and itching associated with cholestatic disease, the often-silent progression of metabolic liver injury, and the persistent fear of liver cancer.
For decades, much of liver disease treatment has focused on controlling symptoms, slowing progression, and managing chronic conditions. These advances have saved lives, but for many patients, treatment remains an ongoing necessity rather than a path toward lasting recovery.
At AASLD's The Liver Meeting 2026, emerging research offered a compelling glimpse of what might come next. Across viral hepatitis, metabolic dysfunction-associated steatohepatitis (MASH), and other liver diseases, investigators presented advances that could reshape treatment approaches and bring the possibility of more durable responses, improved quality of life, and, in some cases, functional cures closer to reality.
For those developing the next generation of therapies, these advances also raise important questions. How do we demonstrate that a treatment's benefits will last? How can clinical trials better capture improvements that matter to patients? And how can increasingly complex science be translated into therapies that reach the people who need them?
Three developments from AASLD highlight both the promise of this research and the clinical development challenges that lie ahead.
1. Moving Beyond Lifelong Treatment Toward Durable Responses
For someone living with chronic hepatitis B (HBV) or hepatitis delta (HDV), successful treatment may mean years of viral suppression, regular monitoring, and the ongoing uncertainty of disease progression. Even when treatment is effective, the possibility of stopping therapy without losing that protection can remain out of reach.
That is what makes the pursuit of finite treatment and functional cure strategies so meaningful.
At AASLD, results from Vir Biotechnology's Phase III ECLIPSE 1 study evaluating elebsiran and tobevibart demonstrated encouraging antiviral activity in HDV, with 44% of patients achieving the primary composite endpoint of undetectable HDV RNA and ALT normalization at week 48, compared with 0% in the control group. Longer-term findings from the Phase II SOLSTICE study also suggested the potential for sustained virologic responses following treatment discontinuation in a small group of patients.
In chronic HBV, investigational approaches are increasingly targeting the mechanisms that allow the virus to persist. Early findings for Precision BioSciences' PBGENE-HBV gene-editing therapy demonstrated promising activity against viral markers, while extended findings for AusperBio's AHB-137 provided further support for the potential of functional cure strategies.
Although these approaches remain at different stages of clinical development, they reflect an important shift in scientific ambition: moving beyond controlling viral activity toward achieving sustained responses that could reduce dependence on lifelong treatment.
What does this mean for clinical development?
The prospect of a functional cure introduces a fundamental question: How do we demonstrate that the benefits of treatment will endure after therapy stops?
For sponsors, answering that question requires careful consideration of durability endpoints, treatment discontinuation criteria, sensitive virologic assessments, and long-term follow-up. Novel therapeutic modalities may also introduce additional safety monitoring and biomarker requirements.
These decisions are central to developing the evidence needed to establish whether an initial treatment response can translate into sustained clinical benefit.
For patients who have spent years managing a chronic infection, that distinction could be life-changing.
2. Measuring What Matters: Beyond Biomarkers to Better Lives
Some of the most difficult aspects of living with liver disease are not always captured by traditional measures of treatment response.
For patients with MASH, progressive liver injury can occur silently, with serious complications developing before symptoms become apparent. For those living with primary biliary cholangitis (PBC), persistent itching and fatigue can disrupt sleep, work, and everyday life, even when conventional laboratory measures suggest that treatment is working.
These realities raise an important question for researchers: Are we measuring everything that matters?
At AASLD, emerging therapies for MASH demonstrated encouraging activity across hepatic and metabolic parameters. Phase II findings for Altimmune's pemvidutide highlighted improvements in weight and noninvasive markers associated with fibrosis risk, while data for Rivus Pharmaceuticals' HU6 supported further investigation of approaches targeting cellular metabolism and hepatic fat accumulation.
These findings reflect a growing understanding that treating MASH requires addressing the interconnected metabolic processes contributing to liver injury and disease progression.
In Primary Biliary Cholangitis (PBC), longer-term findings for elafibranor and seladelpar reinforced the importance of sustained biochemical responses alongside symptom management. For patients experiencing debilitating pruritus, meaningful relief can represent more than an improvement in a clinical assessment—it can mean sleeping through the night, returning to normal activities, or regaining a sense of control over daily life.
What does this mean for clinical development?
As therapeutic approaches evolve, so must the strategies used to evaluate their benefits.
In MASH, sponsors face important decisions around patient stratification, noninvasive biomarkers, histological assessments, and endpoints capable of demonstrating meaningful changes in disease activity and progression.
For PBC, incorporating patient-reported outcomes alongside biochemical measures can help provide a more complete picture of treatment benefit.
The challenge is balancing scientific rigor and regulatory expectations with the need to capture outcomes that reflect patients' lived experiences.
Ultimately, clinical development should seek to answer not only whether a therapy changes a biomarker, but whether that change translates into better health and a better life.
3. Turning Complex Science into Treatments Patients Can Access
The promise of scientific innovation is particularly powerful in diseases where effective treatment options remain limited.
In alcohol-associated liver disease (ALD), patients may face rapid deterioration, serious complications, and limited therapeutic alternatives. Beyond the medical challenges, stigma and the complexity of managing alcohol use disorder can create additional barriers to care and participation in clinical research.
For patients and families facing severe disease, the need for more effective interventions is urgent.
Discussions at AASLD highlighted emerging approaches targeting inflammatory pathways, advances in biomarkers that may help identify patients at risk of acute decompensation, and the importance of integrating medical and behavioral health considerations into patient care.
These developments underscore the need to approach liver disease treatment not simply as an effort to address a damaged organ, but as an opportunity to improve the health and well-being of the whole person.
At the same time, novel therapeutic modalities across liver diseases—including gene-editing and RNA-targeted approaches—are creating new possibilities for patients who may not benefit sufficiently from existing treatments.
Yet the path from scientific discovery to an effective therapy is rarely straightforward.
What does this mean for clinical development?
Innovative therapies often bring increasingly complex trial requirements, from specialized biomarker assessments and biopsy procedures to extended safety monitoring and challenging patient recruitment.
For sponsors, successful clinical development requires more than a scientifically compelling protocol. It demands an understanding of the patients being studied, the capabilities of participating sites, and the practical realities of conducting trials across diverse healthcare settings.
This is especially important when patients are managing serious illness, multiple comorbidities, or the burden of frequent assessments and long-term follow-up.
Thoughtful trial design, early site engagement, and coordinated clinical and operational planning can help reduce unnecessary barriers to participation while supporting the collection of reliable evidence.
Because even the most promising scientific breakthrough cannot improve lives unless it can be successfully evaluated and ultimately made available to patients.
Advancing the Science, Improving Lives
The research presented at AASLD 2026 offers reasons for optimism. Across liver diseases, investigators are exploring new ways to achieve durable treatment responses, address underlying disease mechanisms, and improve outcomes that matter to patients.
Important questions remain, and many emerging therapies still have significant development milestones ahead. But the direction of research is encouraging: moving beyond managing disease toward the possibility of lasting improvement and, for some conditions, functional cures.
For biotech sponsors, realizing that potential requires navigating complex scientific and clinical development decisions. From selecting meaningful endpoints and identifying appropriate patient populations to managing specialized assessments and long-term follow-up, every decision can influence the path from discovery to treatment.
At Novotech, we recognize that behind every clinical trial is the hope of bringing a meaningful new treatment to patients. With experience supporting more than 200 liver disease studies globally, we work alongside biotech sponsors, investigators, and research sites to address the scientific and operational challenges of advancing innovative therapies.
The ultimate measure of progress is not simply the number of promising results presented at a scientific conference. It is what those advances may eventually mean for the people living with these diseases: fewer limitations, better health, more time with loved ones, and the possibility of a future no longer defined by their condition.





